Company: KROS
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001664710-25-000018
Chunk: 55

Company: Keros Therapeutics, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 9B
Chunk 55
---
 Net cash provided by financing activities391,821 178,956 120,309 NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH229,021 51,984 49,006 Cash, cash equivalents and restricted cash at beginning of year332,359 280,375 231,369 Cash, cash equivalents and restricted cash at end of year$561,380 $332,359 $280,375 SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:Property and equipment purchases in accounts payable$— $599 $75 Issuance costs in accrued and accounts payable$— $— $63 Right-of-use assets obtained in exchange for operating lease obligation$5,737 $1,338 $15,423  

The following table provides a reconciliation of the cash and cash equivalents and restricted cash as of each of the periods shown above:

YEAR ENDED DECEMBER 31,202420232022Cash and cash equivalents$559,931 $331,147 $279,048 Restricted cash1,449 1,212 1,327 Total cash, cash equivalents and restricted cash$561,380 $332,359 $280,375 

See notes to consolidated financial statements.

F-7

KEROS THERAPEUTICS, INC.

Notes to Consolidated Financial Statements

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION

Keros Therapeutics, Inc. (“Keros” or the “Company”) was incorporated in 2015 as a Delaware corporation. Its principal offices are in Lexington, Massachusetts. The Company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins. One of the Company’s product candidates, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension (“PAH”) and for the treatment of cardiovascular disorders. The Company's second product candidate, KER-065, is being developed for the treatment of neuromuscular diseases. The Company’s most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts (“cytopenias”), including anemia and thrombocytopenia, in patients with myel